CRDF Mani Mohindru bought Cardiff Oncology, Inc. shares — SEC Form 4BUYCardiff Oncology, Inc.

Mani Mohindru, Chief Executive Officer at Cardiff Oncology, Inc. (CRDF), bought 24,703 shares at $1.21 ($30K) on 2026-06-18, disclosed to the SEC on 2026-06-22.

SEC EDGAR Filing

0001664708-26-000002

View on SEC EDGAR

Why this matters

glm-4.7-flash · 2026-06-22

CEO Mani Mohindru purchased 24,703 shares at $1.21 on June 18, 2026, marking the largest insider purchase in the company's history. This significant buyback by the CEO suggests confidence in the stock's valuation following a 40% year-to-date decline.

Price context

The stock is currently trading at $1.86, representing a 40% drop over the past year and sitting 59.17% below its 52-week high of $4.56.

Catalysts to watch

•CEO Mani Mohindru executed the largest insider purchase in company history on June 18, 2026.
•The company plans to move the 30mg onvansertib dose into a registrational trial in 2026, as announced on January 27, 2026.

Risks

•The company reported a Q4 loss of $7.2 million (11 cents per share) on February 24, 2026.
•Short interest is 0.27% of the float.

AI-generated context from public data. Not investment advice. Verify before trading.

Strong71/100

Clearly above the average filing.

Buying the DipOpportunistic BuyFirst-Time BuyerDeep Dip Buy

Filing Info

Filed2026-06-22

Traded2026-06-18

Accession0001664708-26-000002

SourceSEC EDGAR (Live)

Insider

NameMani Mohindru

TitleChief Executive Officer

PIT GradeInsiderUnrated

View Company View Insider

Related Trades by This Insider

Ticker	Type	Filed	Value	7d Stock	Filing
CRDF	BUY	2026-07-16	$50K	—	Filing →
CARA	SELL	2019-12-04	$162K	—

Get an email when an insider at CRDF files

Free account. Follow CRDF and up to 10 more companies.

Follow CRDF for free

CRDF Mani Mohindru bought Cardiff Oncology, Inc. shares — SEC Form 4BUYCardiff Oncology, Inc.

Filing Info

Insider

Related Trades by This Insider

Trade Details

Outcomes